Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens
about
Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers.Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines updateA phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors.Expression of phospho-mTOR kinase is abundant in colorectal cancer and associated with left-sided tumor localization.Targeting cell death signaling in colorectal cancer: current strategies and future perspectives.Targeted therapy in gastrointestinal malignancies.Targeting mTOR network in colorectal cancer therapyStrategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer.Rationally designed treatment for metastatic colorectal cancer: current drug development strategiesCurrent clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review.Advances in dynamic modeling of colorectal cancer signaling-network regions, a path toward targeted therapies.Therapeutic Potential of Targeting PI3K/AKT Pathway in Treatment of Colorectal Cancer: Rational and Progress.Treatment-related fatigue with everolimus and temsirolimus in patients with cancer-a meta-analysis of clinical trials.
P2860
Q33422778-F3CBC8AC-3716-48B3-8A83-9FD05B42CEB7Q34441837-43BCB573-ADEB-4604-9D24-70C2853A1724Q35896874-04A70576-5F37-4C9A-B2CF-172140207F4FQ35919248-BC9EC3CF-3879-4FFB-B3CC-DBC7CF4AF5FAQ37602717-5031FDFB-FCB0-4072-8F46-F55BA0085D0EQ37702506-8EBEA702-35E5-4DE9-90C5-49B30CA9209AQ37708005-2E2EEE6B-E4EB-41D2-BF2C-9F0FEFBD5B9FQ38238743-6933D52B-FD84-438E-9577-9E2587DA7043Q38240841-28EB7AFA-BC3E-4362-BAE0-9B29E8BD7522Q38242086-05CB137A-61E5-4D90-99D6-787E4EF87245Q38515841-0B8EEF6F-ACE9-480B-9167-7561A4B2FFFEQ38910834-EA86EC38-9B57-4B44-81F0-5776CDE328E4Q38946538-3FDD21AF-EA04-4E2F-A6A1-6096712B2722Q46909057-9C2B01D1-F3A9-4A2B-BA81-F63D109EE7E3
P2860
Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase II study of everolimus i ...... and irinotecan-based regimens
@en
Phase II study of everolimus i ...... and irinotecan-based regimens.
@nl
type
label
Phase II study of everolimus i ...... and irinotecan-based regimens
@en
Phase II study of everolimus i ...... and irinotecan-based regimens.
@nl
prefLabel
Phase II study of everolimus i ...... and irinotecan-based regimens
@en
Phase II study of everolimus i ...... and irinotecan-based regimens.
@nl
P2093
P2860
P1476
Phase II study of everolimus i ...... and irinotecan-based regimens
@en
P2093
David P Ryan
Edward R Arrowsmith
Emilio Bajetta
Jimmy Hwang
Kamel Malek
Michaela Sedova
Salvatore A Del Prete
Sunil Sharma
P2860
P304
P356
10.1158/1078-0432.CCR-13-0027
P407
P577
2013-06-06T00:00:00Z